A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.

NCT ID: NCT06005441

Last Updated: 2024-12-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 173 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-11-10
• Study Completion Date: 2024-10-18

Brief Summary

This is a randomized, placebo-controlled, Phase 2b study to evaluate the efficacy, safety, and tolerability of CBL-514 injection compared with CBL-A1 and CBL-A2 for reducing subcutaneous fat.

Detailed Description

A total of approximately 160 adult participants with moderate or severe abdominal fat at Screening will be enrolled. Each participant will receive up to 4 treatments of allocated study drug administered subcutaneously to the abdomen, once every 3 weeks.

Conditions

Subcutaneous Fat

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

CBL-514 Injection

Participant will receive CBL-514 administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 3 weeks for up to 4 treatments.

Group Type: EXPERIMENTAL

CBL-514 injection

Intervention Type: DRUG

Provided as a ready for use injectable CBL-514 solution

CBL-A1 Injection

Participant will receive CBL-A1 administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 3 weeks for up to 4 treatments.

Group Type: EXPERIMENTAL

CBL-A1 Injection

Intervention Type: DRUG

Provided as a ready for use injectable CBL-A1 solution

CBL-A2 Injection

Participant will receive CBL-A2 administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 3 weeks for up to 4 treatments.

Group Type: EXPERIMENTAL

CBL-A2 Injection

Intervention Type: DRUG

Provided as a ready for use injectable CBL-A2 solution

0.9% Sodium Chloride

Participant will receive 0.9% Sodium Chloride administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 3 weeks for up to 4 treatments.

Group Type: PLACEBO_COMPARATOR

0.9% Sodium Chloride

Intervention Type: DRUG

Sodium Chloride (0.9% NaCl) placebo for injection

Interventions

CBL-514 injection

Provided as a ready for use injectable CBL-514 solution

Intervention Type: DRUG

CBL-A1 Injection

Provided as a ready for use injectable CBL-A1 solution

Intervention Type: DRUG

CBL-A2 Injection

Provided as a ready for use injectable CBL-A2 solution

Intervention Type: DRUG

0.9% Sodium Chloride

Sodium Chloride (0.9% NaCl) placebo for injection

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female, aged 18 years to 64 years old (at Screening), inclusive.

2. Body mass index (BMI) >18.5 and < 30 kg/m2 and body weight ≥ 50 kg at Screening and Day 1.

3. Participant has abdominal fat graded by the Investigator as Grade 3(moderate) or Grade 4(severe) using the Clinician-Reported Abdominal Fat Rating Scale at Screening.

4. Participant has stable body weight (identified as ≤ 3 kg weight change per participant report) for at least 3 months before Screening and during the study.

5. Participant who has maintained a stable lifestyle (e.g., exercise, eating patterns, and smoking habit) per participant report for at least 3 months before Screening and during the study.

6. Voluntarily signs the Informed Consent Form and, in the opinion of the Investigator or delegate, is physically and mentally capable of participating in the study and willing to adhere to study procedures.

Exclusion Criteria

1. Female participant of childbearing potential who is not willing to commit to an acceptable contraceptive regimen from the time of Screening and throughout study participation until 90 days after the last IP dose, or who is currently pregnant or lactating. Male participant who is not willing to commit to using a condom and refraining from sperm donation from the time of the first dose of IP, throughout study participation until 90 days after the last IP dose.

2. Participant diagnosed with coagulation disorders or who is receiving anticoagulant/antiplatelet therapy or medications or dietary supplements that impede coagulation or platelet aggregation.

3. Participant has hemoglobin A1c (HbA1c) ≥9%, delayed wound healing, or poorly controlled diabetes in the opinion of Investigator, make the individual an inappropriate candidate for the study.

4. Participant with active or prior history of malignancies within 5 years before Screening or currently being evaluated for a possible malignancy at Investigator's discretion.

5. Participant with a history of human immunodeficiency virus (HIV)-1 infection or active HIV infection at Screening with positive HIV antigen/antibody combo test.

6. Participant with a history of trypanophobia, the extreme fear of medical procedures involving injections or needles, or who experiences vasovagal syncope or faints at the sight of blood or a needle.

7. Participant with folding fat or skin on abdomen in standing position.

8. Participant with severe or very severe abdominal visceral fat.

9. Participant with ventral abdominal or umbilical hernia or previous repair of same.

10. Participant has abnormal skin or local skin conditions at the treatment area, which, in the opinion of Investigator, would increase risk to the participant or inhibit safety and efficacy evaluation.

11. Participant who has undergone the following procedures:

1. Previous surgery that caused scar tissues on the anticipated treatment area before Screening or during the study.

2. Liposuction or abdominoplasty to the region to be treated before Screening or during the study.

3. Aesthetic procedure for body contouring or fat reduction to the region to be treated within 12 months before Screening or during the study.

4. Using medication that is delivered via subcutaneous injection at the treatment area within 4 weeks before Screening or during the study.

12. Participant with contraindications to MRI imaging

13. Participant is on prescription or OTC weight reduction medication, weight reduction program, or any GLP-1 agonist (e.g., semaglutide, terzepatide, liraglutide, etc.) (oral or injectable) within 6 months before Screening or during the study.

14. Participant is undergoing chronic steroid or immunosuppressive therapy.

15. Requiring continual use of any medication that is known to strongly inhibit or induce CYP1A2 enzymes, sensitive CYP1A2 substrates or drugs with narrow therapeutic index during the study that, in the opinion of the Investigator, may affect the evaluation of the study product or place the participant at undue risk.

16. Unable to receive local anesthesia.

17. Participant with known allergies or sensitivities to the IP or its components.

18. Participant with liver cirrhosis, with inadequate liver function at Screening.

19. Participant with any renal impairment.

20. Use of any investigational drug or device within 3 months prior to Screening.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 64 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Caliway Biopharmaceuticals Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Anne Sheu

Role: STUDY_DIRECTOR

Caliway Biopharmaceuticals Co., Ltd.

Locations

Investigational Site 1

Omaha, Nebraska, United States

Countries

United States

Other Identifiers

CBL-0205

Identifier Type: -

Identifier Source: org_study_id